LLY - Eli Lilly and Company
| Previous Close | 106.07 |
| Open | 106.23 |
| Bid | 105.50 x 1100 |
| Ask | 107.05 x 1000 |
| Day's Range | 105.35 - 106.87 |
| 52 Week Range | 73.69 - 107.84 |
| Volume | 5,333,680 |
| Avg. Volume | 3,547,653 |
| Market Cap | 106.064B |
| Beta | 0.48 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.14 |
| Earnings Date | Oct 23, 2018 |
| Forward Dividend & Yield | 2.25 (2.13%) |
| Ex-Dividend Date | 2018-08-14 |
| 1y Target Est | 98.07 |
- CNBC Videos•2 days ago
Elanco CEO on IPO, animal health focus
Jeff Simmons, Elanco CEO, discusses the animal health company's initial public offering at the NYSE.
- The Wall Street Journal•19 hours ago
[$$] Lilly Approval to Spur Migraine-Prevention Market in Europe
& Co.’s (LLY) preventive migraine drug galcanezumab has received a positive marketing recommendation from the European Medicines Agency, the company and the regulator said separately on Friday, opening the door to competition in Europe. The approval matters because the drug is one of a new class of compounds that inhibit the activity of a molecule involved in migraine attacks, for which there is currently no cure. Ltd. (TEVA) also received approval from the Food and Drug Administration for its own fremanezumab, after months of delays had weighed on investor sentiment.
- Zacks•22 hours ago
Market Rallies Despite Trade Worries: 5 Blue-Chip Picks
The current momentum in stock markets can primarily attributed to large-cap blue-chip stocks as investors shrugged off trade war jitters.
Markit•yesterdaySee what the IHS Markit Score report has to say about Eli Lilly And Co.
Eli Lilly And Co NYSE:LLY
- PR Newswire•yesterday
Lilly Receives Positive CHMP Opinion for Emgality™ (galcanezumab) for the Prophylaxis of Migraine in Adults
INDIANAPOLIS, Sept. 21, 2018 /PRNewswire/ -- Eli Lilly and Company (LLY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Emgality™ (galcanezumab) for the prophylaxis of migraine in adults who have at least four migraine days per month. In June 2018, Lilly announced the intended brand name, Emgality™, was conditionally accepted by the U.S. Food and Drug Administration (FDA). Emgality is an investigational, once-monthly, self-administered injection under evaluation for the prevention of migraine, with no titration needed.
- Reuters•yesterday
Lilly migraine drug wins European panel thumbs-up
A European Medicines Agency panel on Friday recommended the approval of U.S. pharmaceutical group Eli Lilly's migraine treatment, bringing the drug one step closer to being sold in the European Union. Emgality, or galcanezumab, which treats episodic cluster headache attacks, was endorsed by the Committee for Medicinal Products for Human Use, a panel whose recommendations are generally followed by European regulators. Lilly's drug belongs to a new class of drugs targeting CGRP to treat migraines.
Reuters•2 days agoAnimal health firm Elanco surges 41 percent on debut
The company raised $1.51 billion from the offering, which it expects to largely pass on to Eli Lilly and Co (LLY.N). The U.S. drugmaker is expected to own about 82.3 percent of Elanco after the IPO, which was announced in July following a nine-month review of Lilly's businesses which include diabetes and lung cancer drugs.
- MarketWatch•2 days ago
Elanco Animal Health stock soars more than 35% in trading debut
Elanco Animal Health Inc. shares soared more than 35% Thursday in their trading debut, after the company priced the stock above its price range. Elanco, a spinoff from Eli Lilly & Co. , issued 62.9 million shares at $24 each, compared with a price range of $20 to $23, to raise $1.51 billion. Goldman Sachs. J.P. Morgan and Morgan Stanley were book-running managers on the deal. Shares are trading on the New York Stock Exchange under the ticker "ELAN."
- Zacks•2 days ago
Eli Lilly Prices Animal Health Unit IPO at $24 Per Share
Lilly (LLY) prices Elanco IPO at $24 per share which is above the expected range of $20-$23 per share.
- Market Realist•2 days ago
Pharma Stocks: GlaxoSmithKline’s Revenue Trend and 2018 Estimates
GlaxoSmithKline reported a nearly flat top line at 7.3 billion pounds, including a 4% rise in operating revenue offset by a 4% negative foreign exchange impact. GlaxoSmithKline’s business is divided into three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare.
- MarketWatch•2 days ago
Elanco’s $1.7 billion IPO looks too pricey, and here’s why
Elanco Animal Health, the premier animal-health company being spun out of Eli Lilly (LLY) , is expected to begin trading on Thursday. Elanco enters the public market with significant revenue ($2.9 billion in 2017) but falling after-tax profit (NOPAT), and negative GAAP net income. As with any health-care firm, the valuation is based less on current profitability and more on the strength of its product/vaccine portfolio (and their patents) and its success in researching and developing (or acquiring) new animal-health products.
- Reuters•3 days ago
Lilly's Elanco animal health unit's IPO priced at $24/share
The initial public offering of Eli Lilly Co's animal health unit, Elanco, was priced above the expected range at $24 per share on Wednesday, giving the company a market capitalization of $8.55 billion. Elanco raised $1.51 billion from the IPO of 62.9 million shares. Lilly, which sold only a minority stake in the IPO, announced the separation of the unit in July following a nine-month review.
- MarketWatch•3 days ago
Elanco Animal Health prices IPO above expected range
Elanco Animal Health Inc. priced shares for its initial public offering above the estimated range late Wednesday. The animal drug company, which is being spun off from Eli Lilly & Co. , priced shares at $24 a piece. Earlier in the month, Elanco had estimated shares in the $20 to $23 range. Under current pricing, Elanco hopes to raise up to $1.74 billion on an offering of 62.9 million shares with an added 9.4 million to underwriters to cover over-allotments. Following the IPO, Lilly expects to keep an 82.3% stake in Elanco, or 80.2% if over-allotment shares are sold. Goldman Sachs. J.P. Morgan and Morgan Stanley are acting as book-running managers. Shares are scheduled to begin trading under the ticker "ELAN" on the New York Stock Exchange on Thursday.
- Business Wire•3 days ago
Elanco Announces Pricing of Initial Public Offering
The shares are expected to begin trading on the New York Stock Exchange (NYSE) on September 20, 2018 under the ticker symbol “ELAN.” The offering is expected to close on September 24, 2018, subject to customary closing conditions. Elanco has granted the underwriters a 30-day option to purchase up to 9.435 million additional shares of common stock at the initial price to the public less underwriting discounts. Following the IPO, Lilly is expected to hold approximately 82.3% of Elanco (80.2% if the underwriters' option to purchase more shares is exercised in full).
- Bloomberg•3 days ago
Lilly's Elanco Rises After $1.5 Billion Animal-Health IPO
The Eli Lilly & Co.-owned animal medicine maker rose to $32.11 from its $24 offering price at 11:40 a.m. Thursday in New York trading, giving it a market value of $11.7 billion. Elanco priced 62.9 million shares on Wednesday, after marketing them at $20 to $23 each. Elanco already operates fairly independently from its soon-to-be former parent, which will help it move quickly once it’s on its own, according to Chief Executive Officer Jeff Simmons.
- Zacks•3 days ago
J&J Files NDA for Erdafitinib in Urothelial Cancer Indication
Johnson & Johnson (JNJ) submits regulatory application to the FDA seeking approval of pan-FGFR inhibitor, erdafitinib, for the treatment of metastatic urothelial cancer, a type of bladder cancer.
- Zacks•3 days ago
Novo Nordisk to Restructure R&D Unit & Lay Off 400 Staff
Novo Nordisk (NVO) plans to restructure and reallocate resources in its Research and Development organization and lay off 400 employees from the unit.
- Market Realist•3 days ago
Pharma Stocks in Review: A Valuation Comparison
In this article, we’ll compare the valuations of Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK).
- Zacks•4 days ago
Bayer (BAYRY) Focuses on Acquisitions, Competition a Concern
Bayer (BAYRY) focuses on acquisitions and deals in order to boost growth as well as portfolio.
- Market Realist•4 days ago
Exploring Pharmaceutical Stocks’ Revenue Growth Rates
In this article, we’ll compare the revenue growth rates of the pharmaceutical companies under review in this series: Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK).
- Market Realist•4 days ago
A Look at the Dividends Paid by Pharma Stocks in 2018
In this article, we’ll discuss the details of the dividends paid by pharmaceutical stocks Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK).
- Zacks•5 days ago
Glaxo Seeks EU Approval for Two-Drug Regimen in First-Line HIV
Glaxo (GSK) submits a regulatory application in the EU for a single-tablet, two-drug regimen of dolutegravir and lamivudine for the first-line treatment of HIV-1 infection.
- Market Realist•5 days ago
Analysts Raise Ratings on Teva Stock on Ajovy’s FDA Approval
On September 14, Teva Pharmaceutical Industries (TEVA) announced the FDA approval of Ajovy (fremanezumab), its injectable migraine drug. Following the news, a number of analysts raised their recommendations and target prices on Teva Pharmaceutical Industries.
- Market Realist•5 days ago
How Pharmaceutical ETFs Have Performed in 2018
Pharmaceutical ETFs are securities that are publicly traded on stock markets designed for investors who don’t have the capacity to hold many stocks but are interested in diversification within the pharmaceutical sector.
Market Realist•5 days agoCompetition Dynamics for Ajovy—Teva’s Migraine Drug
Teva Pharmaceutical Industries (TEVA) received FDA approval for its Ajovy (fremanezumab-vfrm) injectable on September 14. The chart below shows the company’s quarterly sales trend. The marketing application for Ajovy was filed by Teva in Europe in February. Teva’s (TEVA) Ajovy is an anti-CGRP (calcitonin gene-related peptide) migraine prevention treatment and offers monthly and quarterly dosage options.
